Supportive care

OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Holtick U et al. Eur J Haematol. 2015 Feb 23. doi: 10.1111/ejh.12541. [Epub ahead of print]. Use of allogeneic platelet gel in the management of chemotherapy extravasation injuries: a case report. Di Costanzo G et al. Onco…

Details

General

The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence. Hostenkamp G et al. Soc Sci Med. 2015 Feb 7;130C:162-171. doi: 10.1016/j.socscimed.2015.02.003. [Epub ahead of print]. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. Ashjian E et al. J Oncol Pharm Pract. 2015 Feb 17. pii: 1078155215572036. [Epub ahead of print]. Advance…

Details

Complications of myeloma and its treatments

Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment. Wang L et al. Clin J Oncol Nurs. 2015 Feb 1;19(1):E4-7. doi: 10.1188/15.CJON.E4-E7. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Peng L et al. Support Care Cancer. 2015 Feb 13. [Epub ahead of print]. Renal insufficiency retains adverse prognostic implications despite renal function improvement following…

Details

Diagnostic tests and prognostic indicators

18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma: A Comparative Study. Fonti R et al. Clin Nucl Med. 2015 Jan 20. [Epub ahead of print]. Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. Dimopoulos MA et al. J Clin Oncol. 2015 Jan 20. pii: JCO.2014.57.9961. [Epub…

Details

Emerging treatments

Multiple Myeloma Yields to CD38 Inhibitors. [No authors listed]. Cancer Discov. 2015 Jan 16. [Epub ahead of print]. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Atrash S et al. Blood Cancer J. 2015 Jan 16;5:e272. doi: 10.1038/bcj.2014.93. Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant. Mangiacavalli S et al. Leuk…

Details

Biology and genetics

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02. Leleu X et al. Blood. 2015 Jan 9. pii: blood-2014-11-612069. [Epub ahead of print]. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. Puig N et al. Leukemia. 2015 Jan 8. doi: 10.1038/leu.2015.7. [Epub ahead of print]. Combined immune checkpoint protein blockade…

Details

Supportive care

Plasmapheresis in cast nephropathy: yes or no? Madore F. Curr Opin Nephrol Hypertens. 2015 Jan 14. [Epub ahead of print]. Antimicrobial peptides: an alternative for innovative medicines? da Costa JP et al. Appl Microbiol Biotechnol. 2015 Jan 15. [Epub ahead of print]. Outcomes following surgical intervention for impending and gross instability caused by multiple myeloma in the spinal column. Zadnik PL et al. J…

Details

General

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Arroz M et al. Cytometry B Clin Cytom. 2015 Jan 23. doi: 10.1002/cyto.b.21228. [Epub ahead of print]. Novel agents have a significant impact on survival of patients with multiple myeloma. Lamm W et al. Wien Klin Wochenschr. 2015 Jan 22. [Epub ahead of print]. Multiple myeloma. Mehta A. Hematology. 2015 Jan;20(1):58-9. doi: 10.1179/1024533214Z.000000000333.…

Details